FDA Rejects Johnson & Johnson's RA Drug Sirukumab, More Safety Data Needed Post author:Sam Post published:September 24, 2017 Post category:BioPharma September 25, 2017By Alex Keown, BioSpace.com Breaking… Source: BioSpace You Might Also Like Bay Area Versartis's Stock Collapses as Growth Hormone Drug Flunks Phase III Test September 21, 2017 ADM Tronics Reports Fiscal Year 2017 June 29, 2017 Effective Immediately: Advaxis CEO Resigns, Interim Leader Named July 6, 2017
